Sana Biotechnology Appoints Brian Piper as CFO Ahead of Key Clinical Data Readouts
核心洞察
Sana Biotechnology has appointed Brian Piper (搜索) as Executive Vice President and Chief Financial Officer, bringing over 25 years of biopharmaceutical financial expertise to the engineered cell therapy company.
The company expects to generate initial clinical data for SC451 in type 1 diabetes (搜索) treatment and SG293 (搜索) in B-cell related diseases within the next 12-18 months.
Piper previously served as CFO at Scorpion Therapeutics (搜索) until its acquisition by Eli Lilly in 2025, and brings experience in capital formation and operational excellence.
Sana Biotechnology has strengthened its leadership team with the appointment of Brian Piper (搜索) as Executive Vice President and Chief Financial Officer, positioning the company for upcoming clinical milestones in its engineered cell therapy programs. The Seattle-based company announced the appointment as it prepares to generate initial clinical data for two key therapeutic candidates within the next 12-18 months.
Strategic Leadership Addition
Piper brings over 25 years of biopharmaceutical financial and operational expertise to Sana, having most recently served as CFO of Scorpion Therapeutics (搜索) and its post-acquisition spin-off, Antares Therapeutics (搜索). His appointment comes as the company advances multiple programs in type 1 diabetes (搜索) and oncology.
"I am thrilled to welcome Brian to Sana and to our leadership team," said Steve Harr (搜索), President and Chief Executive Officer of Sana. "He brings deep expertise in capital formation and disciplined capital allocation along with a proven track record of driving financial and operational excellence."
Clinical Pipeline Progress
The timing of Piper's appointment aligns with significant upcoming data readouts for Sana's pipeline. The company expects to generate initial clinical data for SC451 in the treatment of type 1 diabetes (搜索) and SG293 (搜索) in a B-cell related disease (搜索) over the next 12-18 months, representing important value inflection points for the company.
Harr emphasized the momentum in the company's programs, stating, "We have meaningful momentum in our type 1 diabetes (搜索) and in vivo CAR T programs, and his leadership will be critical as we continue to advance our portfolio, optimize long-term value creation, and work to deliver these transformative therapies for patients."
Extensive Industry Experience
Piper's career spans multiple senior financial roles across the biopharmaceutical industry. He previously served as Chief Financial Officer of Scorpion Therapeutics (搜索) until its acquisition by Eli Lilly in 2025, after which he became CFO of Antares Therapeutics (搜索) following its spin-off from Scorpion. His earlier roles included CFO positions at Prelude Therapeutics, a public biotech company, and Aevi Genomic Medicine (搜索).
Prior to his CFO roles, Piper spent 13 years at Shire Pharmaceuticals (搜索) in senior positions across investor relations, corporate venture capital, and other finance functions. He began his career at Celera Genomics (搜索) and Otsuka Pharmaceuticals (搜索). Piper holds an M.B.A. from the University of Maryland and a B.B.A. from the University of Notre Dame.
Focus on Engineered Cell Therapies
Sana Biotechnology specializes in creating and delivering engineered cells as medicines, with a particular focus on hypoimmune-modified pancreatic islet cells for type 1 diabetes (搜索) and in vivo CAR-T platforms. The company's vision encompasses repairing and controlling genes, replacing missing or damaged cells, and making therapies broadly available to patients.
"I am delighted to join the Sana team at a pivotal time as we build on the demonstrated clinical potential of hypoimmune-modified pancreatic islet cells in type 1 diabetes (搜索) and start clinical development for the in vivo CAR T platform," Piper commented. "I look forward to working closely with the team to ensure a strong balance sheet, drive operational excellence, and apply disciplined capital allocation in support of our vision for patient impact and shareholder value."
The company operates facilities in Seattle, Washington, Cambridge, Massachusetts, and South San Francisco, California, as it advances its portfolio of engineered cell therapies designed to address significant unmet medical needs.